Guest column : Is “evergreening” of drug patents all bad?

A recent article in Health Affairs considers how secondary patenting can extend market exclusivity and delay generic competition.  Amin and Kesselheim examine two key anti-HIV drugs Norvir and Kaletra.

Through the analysis of 108 patents, they find generic competition could be delayed for an additional twelve years beyond the expiration of the patents on the drugs’ base compounds.  Continue reading “Guest column : Is “evergreening” of drug patents all bad?”

India’s move to vanilla generics : Don’t hold your breath

By now, the news that India wants to move away from branded generics and encourage vanilla generics to bring down drug prices has gone around the world.  But all those who think a structural reform of the Indian drug industry is around the corner : stop. And breathe. Continue reading “India’s move to vanilla generics : Don’t hold your breath”

India and clinical trials : in the dock?

India’s Supreme Court has expressed concern at the conduct of clinical trials  asking the government to provide information on the number of trials being conducted, adverse event reports, deaths, compensation to subjects and so on.  Call me an optimist but this could be one of the best things to have happened to the sector in recent years. Continue reading “India and clinical trials : in the dock?”

India and drug pricing : the illusion of closure

A group of ministers (GoM) has put its weight behind a market-based pricing mechanism for 348 essential drugs, a departure from the current practice of pricing a dated list of 74 drugs based on their manufacturing costs.

The GoM decision might suggest that closure to a long-pending issue isn’t far away. But to my mind, its most noteworthy achievement, Continue reading “India and drug pricing : the illusion of closure”